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Abstract 
Background: α-Synuclein (αSYN) has been genetically implicated in familial and sporadic Parkinson’s disease (PD), 
and is associated with disease susceptibility, progression and pathology. Excess amounts of αSYN are toxic to neurons. 
In the brain, microglial αSYN clearance is closely related to neuronal survival. Leucine-rich repeat kinase 2 (LRRK2) is 
the one of the other genes implicated in familial and sporadic PD. While LRRK2 is known to be expressed in microglia, 
its true function remains to be elucidated. In this study, we investigated αSYN clearance by microglia isolated from 
LRRK2-knockout (KO) mice.
Results: In LRRK2-KO microglia, αSYN was taken up in larger amounts and cleared from the supernatant more effec-
tively than for microglia isolated from wild-type (WT) mice. This higher clearance ability of LRRK2-KO microglia was 
thought to be due to an increase of Rab5-positive endosomes, but not Rab7- or Rab11-positive endosomes. Increased 
engagement between Rab5 and dynamin 1 was also observed in LRRK2-KO microglia.
Conclusion: LRRK2 negatively regulates the clearance of αSYN accompanied by down-regulation of the endocytosis 
pathway. Our findings reveal a new functional role of LRRK2 in microglia and offer a new insight into the mechanism 
of PD pathogenesis.
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Background
α-Synuclein (αSYN; SNCA) is one of the key molecules 
involved in familial and sporadic Parkinson’s disease 
(PD) [1–5]; genomic multiplication and point mutations 
in the α-synuclein gene (SNCA) are known to be causal 
factors for the familial parkinsonism forms of PD, PARK1 
and PARK4 [6–9]. αSYN comprises 140 amino acids, 
which form an amphipathic region, a NAC domain, and 
an acidic tail [10]. Because of the hydrophobicity of the 
NAC domain, αSYN easily forms toxic fibrillar struc-
tures, and an excess amount of αSYN induces cell death, 
eventually leading to PD [11–13]. αSYN is expressed in 
neurons, where it is involved in exocytosis in the presyn-
aptic region [14, 15], and its transmission from cell to cell 
has been demonstrated [16–18]. These findings suggest 
that clearance of αSYN in the brain is crucially important 
for prevention of neuronal cell death.
Microglia are immune cells in the brain playing cru-
cial roles in inflammatory responses, scavenging, and 
production of neurotropic factors [19]. Accumulated 
evidence indicates that microglia participate in the patho-
genesis of various neurodegenerative diseases [20, 21]. In 
Alzheimer’s disease, β-amyloid stimulates microglia and 
induces the production of inflammatory cytokines [22]. 
Clearance of β-amyloid by microglia has a critical role in 
prevention of the disease [23, 24]. In PD, microglia are 
involved in both disease -prevention through clearance 
of αSYN and disease -progression through production of 
inflammatory cytokines in which the oligomeric αSYN 
stimulates toll-like receptor (TLR) 2 whereas a high 
amount of monomeric αSYN stimulates TLR4 [25–28]. 
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Among the various types of brain cells, microglia are 
known to have the highest ability to degrade αSYN [29]. 
One study using mice overexpressing αSYN has shown 
that acceleration of microglial clearance through αSYN 
opsonization ameliorated the degree of neurodegenera-
tion [30]. It is believed that achieving adequate degrada-
tion of αSYN might be a new therapeutic approach for 
diseases characterized by pathological accumulation of 
αSYN [31, 32].
Leucine-rich repeat kinase 2 (LRRK2) is the gene 
responsible for autosomal-dominant PD, PARK8, which 
was originally defined by linkage analysis of a Japanese 
family (the Sagamihara family) [33–36]. LRRK2 is a 
complex kinase consisting of LRR, ROC, COR, kinase, 
and WD40 domains [37]. Accumulated evidence sug-
gests that LRRK2 plays a key role in axonal extension, 
autophagy, proliferation, and survival of neurons [38, 
39]. In addition to neurons, LRRK2 is highly expressed in 
immune cells such as B cells, macrophages, and microglia 
[40–43]. Several studies have demonstrated that LRRK2 
is related to inflammatory responses of microglia that 
could be involved in the development and progression 
of neurodegeneration [44, 45]. It has been reported that 
pathological mutations of LRRK2 lead to increased pro-
duction of inflammatory cytokines [46].
With regard to the association between LRRK2 and 
αSYN, it has been reported that LRRK2 knockout (KO) 
attenuates the neuropathology that is induced by αSYN 
overexpression in mouse brain through a delay of neu-
ronal death resulting from improved structure and 
function of the Golgi complex [47]. Another study has 
demonstrated that LRRK2-KO ameliorated neurode-
generation in αSYN-overexpressing rats by inhibiting 
the recruitment of chronically activated proinflamma-
tory myeloid cells [48]. Although these studies suggest 
an association between LRRK2 and the neuropathology 
caused by αSYN, no study has yet addressed how micro-
glial LRRK2 is involved in αSYN clearance.
In the present study, we analyzed microglia treated 
with αSYN and revealed a new functional role of micro-
glial LRRK2. Our results indicate that LRRK2 acts as a 
negative regulator of αSYN clearance.
Results
LRRK2 is a negative regulator of αSYN clearance 
in microglia
To investigate the function of microglial LRRK2, pri-
mary microglia were prepared from LRRK2-KO mice 
and littermate WT control mice by Ni’s method [49]. 
Immunostaining with antibodies against Iba-1 (a micro-
glial marker) and GFAP (an astroglial marker) revealed 
that the purity of the microglia was about 92%. No mor-
phological differences in tomato lectin staining were 
observed between KO and WT microglia (Fig.  1a), and 
the MTT assay demonstrated no difference in viability 
between KO and WT microglia (Fig.  1b). Furthermore, 
the phagocytotic activities of KO and WT microglia did 
not differ from each other when analyzed using fluores-
cent latex beads (Fig.  1c). These results indicated that 
LRRK2 is not related to these microglial phenotypes. 
For evaluation of αSYN clearance, we performed αSYN 
uptake and clearance assay using recombinant αSYN. The 
αSYN treatment did not alter the protein level of LRRK2 
(250  kDa) in WT primary microglia (Fig.  2a). Impor-
tantly, αSYN bands were detected only in the groups 
that had been treated with recombinant αSYN, indicat-
ing that the detected bands were not endogenous but 
exogenous recombinant αSYN. It was noteworthy that 
more αSYN was taken up by KO microglia than by WT 
microglia (Fig. 2b). The results were confirmed using dif-
ferent anti-αSYN and anti-GAPDH antibodies (Fig.  2c, 
d). Measurement of αSYN clearance showed that the 
level of residual αSYN in the culture medium of KO 
microglia was decreased more prominently than that 
in the medium of WT microglia (Fig. 2e). These results 
indicated that αSYN clearance by LRRK2-KO micro-
glia is higher than that by WT microglia, suggesting 
that LRRK2 is a negative regulator of αSYN clearance in 
microglia.
LRRK2 regulates endocytotic αSYN uptake
It has been reported that αSYN is internalized through 
the endocytotic pathway [50]. On the other hand, LRRK2 
is associated with Rab5, a member of the Ras super-
family of small Rab GTPases and a component of the 
(See figure on next page.) 
Fig. 1 Characterization of LRRK2-KO microglia. a Tomato lectin staining of LRRK2-KO and WT microglia. One hundred cells were counted per 
culture well. n = 3 culture wells per group. Scale bar 50 μm. b MTT assay for evaluating the viability of LRRK2-KO and WT microglia in the absence or 
presence of αSYN. The data represent percentage viability relative to culture day 0, and were assessed by ANOVA at each time point (3 h: F = 0.26, 
p = 0.852; 6 h: F = 1.26, p = 0.351; 10 h: F = 0.94, p = 0.465; 24 h: F = 3.61, p = 0.065; 48 h: F = 2.55, p = 0.129; and 96 h: F = 3.46, p = 0.071). n = 3 
culture wells per group. c Phagocytosis assay using FITC-microbeads. Upper panel shows an image of microbead phagocytosis. Scale bar 50 μm. 
Lower panel shows the fluorescence intensity of microbeads taken up by microglia. Forty cells were analyzed per group. The data are expressed as 
mean ± SD and were assessed by Student’s t test. These experiments were carried out three times using independent primary microglia isolated 
from different mice, and a representative image and data are shown
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Fig. 2 Increased αSYN uptake and degradation by LRRK2 KO microglia. a Western analysis of LRRK2-KO microglia treated with αSYN. Lysates were 
prepared from LRRK2- KO and WT microglia treated with or without αSYN and subjected to Western analysis using anti-LRRK2, β-actin, and αSYN 
(C-20) antibodies. b Quantified density of αSYN bands in (a) normalized by the density of β-actin. n = 4 culture wells per group. c Western analysis 
using anti-LRRK2, GAPDH, and αSYN (MJFR1) antibodies. d Quantified density of αSYN bands in (c) normalized by the density of GAPDH. n = 4 
culture wells per group. e Residual αSYN in the culture media of WT and KO microglia. n = 8 culture wells per group. The amounts of αSYN were 
measured by ELISA 48 h after αSYN treatment. In all graphical representations, data are expressed as mean ± SD and were assessed by Student’s t 
test (KO vs. WT); *p < 0.05, **p < 0.01. All experiments were carried out three times using primary microglia isolated from independent mice, and a 
representative image and data are shown
Page 5 of 12Maekawa et al. BMC Neurosci  (2016) 17:77 
early endosome [51, 52]. To elucidate whether LRRK2 
regulates endocytotic αSYN clearance through early 
endosomes, WT and KO microglia treated with recom-
binant αSYN were subjected to immunostaining with 
anti-αSYN and anti-Rab5 antibodies. Internalized αSYN 
was visualized as small particles spread widely in the all 
cell, and in keeping with the results of Western analysis, 
KO microglia showed higher amount of αSYN than WT 
microglia (Fig.  3a). Immunostaining for Rab5 demon-
strated a pattern similar to that of αSYN. Interestingly, 
Rab5-positive early endosomes were obviously increased 
in KO microglia relative to WT microglia. Furthermore, 
as reported previously [53], some of the αSYN taken up 
was co-localized with Rab5-positive early endosomes. 
Relative assessment of co-localization between αSYN 
and Rab5 revealed that the Rcoloc value for KO microglia 
was higher than that for WT microglia (Fig. 3b, c). These 
results suggested that the increased uptake of αSYN by 
LRRK2-KO microglia is associated with an increase of 
early endosomes, i.e. LRRK2 is a down-regulator of the 
endocytotic pathway.
Early endosomes are selectively increased in LRRK2‑KO 
microglia
To investigate whether there is any abnormality in other 
components of the endosomal-lysosomal pathway in KO 
microglia, lysosomes were analyzed by immunostain-
ing with anti-LAMP1 antibody (a lysosome marker) and 
a pH-sensitive molecular probe (a functional lysosome 
marker). In both analyses, the fluorescence intensities did 
not differ from that of WT microglia (Fig. 4a), indicating 
that the structure and function of the lysosome system 
Fig. 3 Increment of endocytotic αSYN uptake by LRRK2-KO microglia. a Confocal immunostaining images of αSYN and Rab5 in KO and WT 
microglia. Scale bar 50 μm. Higher-magnification views of the boxed area show the detail of immunopositive particles. Scale bar 20 μm. b Cytofluoro-
grams for αSYN and Rab5 immunostaining evaluated using the high magnification views of KO and WT microglia. c The αSYN/Rab5 correlation 
coefficient (Rcoloc) values for KO and WT microglia. Ten cells were randomly chosen per group. In all graphical representations, data are expressed 
as mean ± SD and were assessed by Student’s t test; *p < 0.05. The experiment was carried out three times using primary microglia isolated from 
independent mice, and a representative image and data are shown
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were not altered in LRRK2-KO microglia. Immunostain-
ing of the early endosome, late endosome, and recycling 
endosome using antibodies against the marker molecules 
Rab5, 7, and 11, respectively, revealed that the fluores-
cence intensity of Rab5-positive endosomes, but not that 
of Rab7- or 11-positive endosomes, was significantly 
increased in KO microglia relative to WT microglia 
(Fig.  4b). The increment of early endosomes in KO 
microglia was also confirmed by using CellLight (Fig. 4c).
Western analysis using the same antibodies con-
firmed that the level of Rab5 protein was higher in KO 
microglia than in WT microglia (Fig.  5). After treat-
ment with recombinant αSYN, an increase in the level of 
Rab5 protein in KO microglia, although not statistically 
(See figure on previous page.) 
Fig. 4 Increase of early endosomes, but not lysosomes, late, or recycling endosomes, in LRRK2-KO microglia. a Immunostaining for lysosomal 
markers in KO and WT microglia. Lysosomes and acidic lysosomes were visualized using anti-LAMP1 and pHrodo, respectively. b Immunostaining 
for endosomal markers in KO and WT microglia. Early endosomes, late endosomes, and recycling endosomes were visualized using antibodies 
against Rab5, Rab7 and Rab11, respectively. Scale bar 20 μm. Quantification of fluorescence intensity per cell showing an increase of Rab5-pos-
itive endosomes, but not Rab7- and Rab11-positive particles, in KO microglia. Twenty-five cells were analyzed per group. c Visualization of early 
endosomes using CellLight. Twenty-five cells were analyzed per group. In the graphical representation, data are expressed as mean ± SD and were 
assessed by Student’s t test; *p < 0.05. All experiments were carried out three times using primary microglia isolated from independent mice, and a 
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Fig. 5 Higher Rab5 protein level in KO microglia than in WT microglia. Western analysis was performed to determine the protein levels of Rab5, 
Rab7 and Rab11 in KO and WT microglia treated with or without αSYN. The quantified density of each Rab was normalized by the density of 
GAPDH. n = 4 culture wells per group. In all graphical representations, data are expressed as mean ± SD and were assessed by ANOVA (KO vs WT). 
Rab5: F = 4.28, p = 0.028; Rab7: F = 0.96, p = 0.443; and Rab11: F = 0.01, p = 0.999. The experiment was carried out three times using primary 
microglia isolated from independent mice, and a representative image and data are shown
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significant, was also observed. These results indicated 
that early endosomes, but not other endosomes or lys-
osomes, are increased in LRRK2-KO microglia.
LRRK2 controls the primary endocytotic process 
in microglia
Recently, LRRK2 has been reported to associate with 
dynamin 1 in SH-SY5Y neuronal cells [54]. Dynamin 1 
is one of the dynamin GTPase superfamily of molecules 
that modulate fission of the cytoplasmic membrane in 
the endocytosis pathway. To investigate how LRRK2 
knockout affects dynamin 1, triple immunofluorescence 
staining with anti-LRRK2, anti-Rab5, and anti-dynamin1 
antibodies was performed on KO and WT microglia. All 
staining was visualized as particles, and co-localization 
among LRRK2, Rab5, and dynamin1 was observed in pri-
mary microglia (Fig. 6a), in accordance with the previous 
study conducted using SH-SY5Y cells. Analysis of rela-
tive staining intensity showed that the Rcoloc value for 
Rab5 and dynamin 1 was increased in LRRK2-KO micro-
glia relative to WT microglia (Fig.  6b, c). These results 
indicated that LRRK2 down-regulates the coordination 
between Rab5 and dynamin 1, resulting in reduced pro-
duction of early endosomes.
Discussion
In the present study, we clarified for the first time the role 
of LRRK2 in the process of αSYN clearance in micro-
glia. Primary microglia isolated from LRRK2-KO mice 
exhibited increased uptake and clearance of αSYN and 
an increased immunostaining of Rab5-positive early 
endosomes, but not other endosomes or lysosomes. KO 
microglia also showed an increased degree of co-locali-
zation between Rab5 and dynamin 1. This study provides 
the first evidence that LRRK2 in microglia has a negative 
regulatory role in αSYN clearance by the early endocyto-
sis pathway.
Because LRRK2-KO microglia showed up-regulation 
of the endocytosis pathway in both the presence and 
absence of recombinant αSYN, i.e., independently of 
exogenous αSYN, it is likely that autonomous up-regula-
tion of endocytosis in LRRK2-KO microglia is one of the 
Fig. 6 Increased co-localization between Rab5 and dynamin 1 in LRRK2-KO microglia. a Comparison of co-localization of Rab5 and dynamin 1 
between KO and WT microglia. Confocal immunostaining images show LRRK2-, Rab5-, and dynamin1-immunopositive particles in the KO and WT 
microglia. Scale bar 10 μm. b Cytofluorograms of dynamin 1 and Rab5 immunostaining in KO and WT microglia. c The Rcoloc values of dynamin1/
Rab5 in KO and WT microglia. Ten cells were analyzed per group. In the graphical representation, data are expressed as mean ± SD and were 
assessed by Student’s t test; ***p < 0.005. All experiments were carried out three times using primary microglia isolated from independent mice, and 
a representative image and data are shown
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mechanisms for the increment of αSYN uptake and clear-
ance. A recent study has reported that Rab5b, an isoform 
of Rab5, is phosphorylated by LRRK2 at Thr 6, resulting 
in a decreased endocytosis rate in Hela cells [55]. It is 
possible that up-regulation of the endocytosis rate in KO 
microglia could be due to the lack of phosphorylation of 
Rab5b. Our findings also suggested that enhancement of 
the coordination between Rab5 and dynamin 1 is another 
mechanism for the up-regulation of Rab5-positive early 
endosomes. It has been shown that G2019S-mutant 
LRRK2 with higher kinase activity inhibits the co-local-
ization between Rab5 and dynamin 1 [54]. Given that the 
kinase activity of LRRK2 down-regulates the co-localiza-
tion between Rab5 and dynamin 1, knockout of LRRK2 
may enhance their co-localization and lead to an increase 
of Rab5-positive early endosomes. As an another possible 
mechanism, LRRK2 may regulate the amount of the Rab5 
molecule itself. It has been reported that macrophages 
of the LRRK2-KO mouse exhibit an increase of IL-6 
production through increased nuclear translocation of 
NFAT [43]. Because IL-6 is known to increase Rab5, but 
not other Rabs [56], it is possible that the elevated level 
of IL-6 in KO microglia may selectively increase Rab5-
positive early endosomes and consequently promote the 
coordination between Rab5 and dynamin 1.
In contrast to our study, it has recently been reported 
that the protein level of αSYN was comparable between 
LRRK2-KO and WT rats that overexpress αSYN after 
viral transfection [48]. It is possible that the amount of 
virally overexpressed αSYN might far exceed the capacity 
of microglia to clear it. LRRK2 KO has also been reported 
to abrogate the neurodegeneration induced by αSYN 
overexpression in this strain of rat. It is possible that a 
decreased inflammatory response resulting from lack of 
LRRK2, rather than up-regulated αSYN clearance, might 
be responsible for this alleviation of neurodegeneration.
It has been shown that an excess amount of αSYN 
induces neuronal death [11–13], and that continuity of 
this process will eventually cause PD [57]. Because αSYN 
is known to be transmitted from cell to cell, and micro-
glia have the highest ability to clear it [16–18, 29], αSYN 
clearance by microglia, in addition to that by neurons 
themselves, would be of crucial importance for maintain-
ing a healthy brain environment.
Conclusions
We have demonstrated that LRRK2 in microglia may 
function as the offending molecule responsible for neu-
rodegeneration, in terms of down-regulation of αSYN 
clearance. In other words, inhibition of LRRK2 would be 
a potential therapeutic approach for PD.
Methods
Animals
LRRK2 exon 41-KO mice, developed by Hinkle and co-
workers [58], on C57BL/6  J and littermate wild-type 
(WT) mice were used. The mice were housed in a light- 
and temperature-controlled room with water and food 
available ad libitum. For sacrifice, mice were euthanatized 
by cervical dislocation or exsanguination. All procedures 
had been approved by the Animal Experimentation and 
Ethics Committee of Kitasato University.
Antibodies
The following primary antibodies were used: rabbit 
polyclonal anti-α-synuclein antibody (C-20, Santa Cruz 
Biotechnology), rabbit monoclonal anti-α-synuclein 
antibody (MJFR1, Abcam), mouse monoclonal anti-α-
synuclein antibody (4D6, Abcam), rabbit monoclonal 
anti-LRRK2 antibody (MJFF2, Epitomics), rabbit poly-
clonal anti-Iba-1 antibody (Wako), horseradish per-
oxidase (HRP)-labeled mouse monoclonal anti-β-actin 
antibody (ab20272, Abcam), rabbit monoclonal anti-
glyceraldehyde-3-phosphate dehydrogenase antibody 
(GAPDH; 14C10, Cell Signaling Technology), mouse 
monoclonal glial fibrillary acidic protein (GFAP) anti-
body (2A5, Abcam), mouse monoclonal anti-Rab5 anti-
body (Rab5-65, Abcam), rabbit monoclonal anti-Rab5 
antibody (C8B1, Cell Signaling Technology), rabbit mon-
oclonal anti-Rab7 antibody (D95F2, Cell Signaling Tech-
nology), rabbit monoclonal anti-Rab11 antibody (D4F5, 
Cell Signaling Technology), and mouse monoclonal anti-
LAMP1 antibody (H4A3, Abcam).
Isolation of primary microglia
Primary microglia isolation was performed accord-
ing to the method of Ni [49]. Briefly, neonatal brains 
were obtained from WT and LRRK2-KO mice at 2 days 
of birth, then cortex sections were dissected out under 
a microscope and digested with papain for 20  min at 
37  °C. The dispersed cells were suspended in growth 
medium (DMEM; Sigma, 10% FCS; Gibco, penicillin/
streptomycin) and cultured at 40,000 viable cells/cm2. 
After mixed glial cells had become 100% confluent (about 
10 days after plating), the culture flask was tapped gen-
tly until most of the microglia became detached. The iso-
lated microglia were then cultured in growth medium at 
10,000 viable cells/cm2 on poly-l-lysine (Sigma)-coated 
cover slips or in 24-well plastic tissue culture plates. The 
cells were used for experiments two days after plating. 
The purity of the microglia was about 92% when deter-
mined by immunostaining with the anti-Iba-1 antibody 
and anti-GFAP antibody.
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Measurement of αSYN uptake
Primary microglia were treated with 5  μg/ml recombi-
nant αSYN [γ-peptide] for 24 h. Uptake of recombinant 
αSYN was analyzed by Western analysis and immunoflu-
orescence staining using the anti-αSYN antibody.
Measurement of αSYN clearance
Primary microglia were treated with 250 pg/ml recombi-
nant αSYN for 48 h. After incubation, the level of resid-
ual αSYN in the culture medium was measured with a 
SensoLyte™ Anti-alpha-Synuclein Quantitative ELISA 
Kit (Anaspec) in accordance with the manufacturer’s 
protocol.
Western blotting
Microglia were lysed in TNE buffer [10  mM Tris–HCl 
buffer (pH 7.6) containing 150  mM NaCl, 1% Nonidet 
P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 
and protease inhibitor cocktail (Roche)] and incubated at 
4  °C for 1 h. The cell lysate was obtained by centrifuga-
tion at 13,000 rpm for 15 min at 4 °C, then subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) using 5–20% gradient e-PAGEL (ATTO), 
and blotted onto polyvinylidene fluoride (PVDF) mem-
branes. The membranes were blocked in 2% skim milk 
in phosphate-buffered saline (PBS)—0.1% Tween 20 for 
60 min at room temperature, and then probed with the 
appropriate primary antibodies for 24  h at 4  °C. After 
incubation with secondary antibodies for 30 min at room 
temperature, protein bands were visualized using an ECL 
Western Blotting Detection Kit (GE Healthcare). The 
intensity of the protein bands was analyzed using NIH 
ImageJ software (http://rsbweb.nih.gov/ij/).
Tomato lectin staining
Primary microglia attached to cover slips were fixed with 
4% paraformaldehyde for 30  min at room temperature 
and reacted with biotin-conjugated tomato lectin (Vector 
Laboratories) for 30  min at room temperature. Avidin/
biotinylated HRP complex and ImmPACT DAB Sub-
strate (Vector Laboratories) were used for detection.
Immunofluorescence staining
After treatment with 2% BSA in PBS—0.2% Triton X-100 
for 60  min at room temperature to block non-specific 
binding, the fixed microglia were incubated with pri-
mary antibodies for 24  h at 4  °C, and subsequently 
with appropriate secondary antibodies for 30  min at 
room temperature. Nuclear staining was performed 
with 2′-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-
2,5′-bi-1H-benzimidazole (Hoechst 33342, Dojindo). 
Visualization of early endosomes using CellLight Early 
Endosomes-GFP (Molecular probes) was conducted 
according to the manufacturer’s protocol. Fluorescent 
signals were observed using a Nikon C2 Si confocal 
microscope system using 525–575, 595–635, and 445–
475 nm band pass filter to obtain the signal by 488 nm-, 
561 nm-, and UV-laser excitation, respectively. Pearson’s 
correlation coefficient (Rcoloc) value was given by Coloc 
2-plugin in ImageJ for each cell.
3‑(4,5‑Dimethylthiazol‑2‑yl) 2,5‑diphenyltetrazolium 
bromide (MTT) assay
The culture supernatants of primary microglia cultured 
for 1, 3, 6, 12, 24, and 48 h with or without recombinant 
αSYN were assayed for viability using a Cell Counting 
Kit-8™ (Dojindo) in accordance with the manufacturer’s 
protocol.
Phagocytosis assay
Primary microglia were incubated with fluorescent latex 
beads (0.0025%, Sigma) for 1  h. The cells were washed 
with PBS, fixed with 4% paraformaldehyde, and mounted 
on glass slides using ProLong® Gold antifade reagent 
(Molecular Probes). Fluorescence intensity per cell was 
determined using ImageJ software.
Statistical analysis
All data are expressed as mean ± S.D. Significance of dif-
ferences was assessed by Student’s t test for two compari-
sons and one-way ANOVA for multiple comparisons.
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GFAP: monoclonal glial fibrillary acidic protein; KO: knockout; LRRK2: leucine-
rich repeat kinase 2; MTT assay: 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide assay; PBS: phosphate-buffered saline; PD: Parkinson’s 
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